Drug news
CHMP recommends Ryzodeg(Novo Nordisk) for treatment of Diabetes Mellitus
On 18 October 2012 the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ryzodeg (insulin degludec) from Novo Nordisk, 100 units/ml and 200 units/ml, solution for injection, intended for the treatment of Diabetes Mellitus. The benefits with Ryzodeg are its ability to lower blood glucose levels and a lower risk of nocturnal hypoglycaemia when compared with insulin glargine. Despite positive effects on nocturnal hypoglycaemia overall hypoglycaemia remained the most common side effect. Insulin degludec is known as Tresiba in the U.S.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins